In a groundbreaking partnership between the Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru, a new ray of hope has emerged for cancer patients undergoing radiotherapy. Their joint effort has led to the creation of AKTOCYTE tablets, a significant step towards improving the lives of these patients. Collaborating with experts from Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; and Advanced Centre for Training Research and Education in Cancer, Navi Mumbai, IDRS Labs aimed to reduce the side effects of radiotherapy.
The results of AKTOCYTE tablets are nothing short of remarkable, especially for pelvic cancer patients experiencing radiotherapy-induced Cystitis (Blood in urine). These patients showed incredible recovery, eliminating the necessity for surgical bladder removal. These tablets, designed to complement cancer radiotherapy, act as a regenerative nutraceutical, immunomodulator, and antioxidant, signifying a major advancement in cancer treatment.
Having obtained approval from the Food Safety and Standards Authority of India (FSSAI) under the Ministry of Health & Family Welfare, Government of India, AKTOCYTE tablets assure both healthcare professionals and patients of their safety and effectiveness.
Key Points:
-
Pelvic Cancer Recovery: AKTOCYTE tablets have shown exceptional effectiveness in pelvic cancer patients undergoing radiotherapy, reducing the need for surgery.
-
Multi-Purpose Solution: Beyond mere supplementation, AKTOCYTE serves as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, showcasing its versatility.
-
Regulatory Assurance: FSSAI approval ensures the safety and quality of AKTOCYTE tablets, instilling confidence in their reliability for healthcare professionals and patients.
-
Market Arrival: Expected to debut in January 2024, AKTOCYTE tablets promise to revolutionize cancer treatment protocols.
The collaboration between the Department of Atomic Energy and industry has been pivotal in achieving this breakthrough. This development signifies a significant moment where scientific innovation meets practical solutions in cancer care.
© Copyright 2023. All Rights Reserved Powered by Vygr Media.
